Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00671398Phase 3Completed
Phase 3, randomised, double-blind trial of ramelteon in Insomnia (3 arms), sponsored by Takeda. Primary endpoint: Latency to Persistent Sleep at Day 1. Started Dec 2002; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00671398.